维利帕尼、紫杉醇给药方案及胚系BRCA状态对浆液性卵巢癌初始治疗的影响——VELIA试验的辅助数据分析
VELIA三期试验的辅助分析按紫杉醇给药方案和胚系BRCA状态分层,分析1132例初治卵巢癌患者。汇总治疗组中剂量密集紫杉醇较每3周方案中位无进展生存期更长(意向治疗人群20.5 vs 15.7个月,HR 0.77)。全程维利帕尼在两种紫杉醇方案中均优于对照组,胚系BRCA状态不影响安全性。
要点
- 剂量密集紫杉醇较每3周方案延长中位无进展生存期:意向治疗人群20.5 vs 15.7个月(HR 0.77)。
- 全程维利帕尼优于对照组:剂量密集亚组24.2 vs 18.3个月(HR 0.67),每3周亚组19.3 vs 14.6个月(HR 0.69)。
- 剂量密集紫杉醇的3/4级中性粒细胞减少、疲乏和贫血发生率高于每3周方案;胚系BRCA突变与野生型亚组间毒性无差异。
核心结论
- 剂量密集紫杉醇可耐受,且在同源重组修复 proficient 和胚系BRCA野生型组中较每3周方案与更长的无进展生存期相关。
- 胚系BRCA状态不影响安全性。
研究设计与样本
- VELIA试验(NCT02470585)为三期随机对照试验,初治卵巢癌女性按1:1:1随机分为全程维利帕尼组、维利帕尼仅联合化疗组和对照组。
- 化疗为卡铂联合紫杉醇,紫杉醇方案为剂量密集(每周)或每3周,由研究者随机前自主选择,为随机分层因素。
- 本分析按紫杉醇给药方案分析1132例患者,安全性按紫杉醇方案和胚系BRCA状态分析。
主要发现
- 汇总治疗组中,剂量密集紫杉醇(n=586)较每3周方案(n=546)中位无进展生存期更长:意向治疗人群20.5 vs 15.7个月(HR 0.77)。
- 同源重组修复 proficient 癌:剂量密集组15.1个月 vs 每3周组11.8个月(HR 0.64)。
- BRCA野生型:剂量密集组18.0个月 vs 每3周组12.9个月(HR 0.70)。
- 全程维利帕尼优于对照组:剂量密集亚组无进展生存期24.2 vs 18.3个月(HR 0.67),每3周亚组19.3 vs 14.6个月(HR 0.69)。
- 剂量密集紫杉醇的3/4级中性粒细胞减少、疲乏和贫血发生率高于每3周方案;胚系BRCA突变(n=211)与野生型(n=902)亚组间毒性无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (gBRCA) status. METHODS: Women with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W) paclitaxel (a stratification factor at randomization), selected at the investigator's discretion pre-randomization. PFS was assessed by paclitaxel dosing schedule using a Cox proportional hazard model adjusted by treatment arm and stratification factors; safety was analyzed based on paclitaxel dosing schedule and gBRCA status. RESULTS: 1132 patients were analyzed by paclitaxel schedule. Pooled treatment arms demonstrated longer median PFS with DD (n = 586) versus Q3W (n = 546) paclitaxel (ITT: 20.5 vs 15.7 months, hazard ratio [HR] 0.77; homologous recombination proficient cancer: 15.1 vs 11.8 months, HR 0.64; BRCAwt: 18.0 vs 12.9 months, HR 0.70). Comparison between arms favored veliparib-throughout versus control in both DD (PFS, 24.2 vs 18.3 months, hazard ratio 0.67) and Q3W (19.3 vs 14.6, hazard ratio 0.69) subgroups. DD paclitaxel was associated with higher incidence of Grade 3/4 neutropenia, fatigue, and anemia versus Q3W. There were no differences in toxicity between gBRCAm (n = 211) and gBRCAwt (n = 902) subgroups. CONCLUSIONS: DD paclitaxel was tolerable and associated with longer PFS in the HR proficient and gBRCAwt groups, versus Q3W. gBRCA status did not impact safety.
引用
- Aghajanian C, Swisher EM, Okamoto A, et al. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2021. PMID: 34930617. doi:10.1016/j.ygyno.2021.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。